Drug Trial Radar · NCT05970289
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Aug 22, 2023
Primary completion
Jul 16, 2025
Study completion Jan 23, 2026
Sponsor
- Lead sponsor
- Brii Biosciences LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Vir Biotechnology, Inc.
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
Conditions
- Chronic Hepatitis B Virus Infection
Interventions
PEG-IFNαBiological
PEG-IFNα will be given via subcutaneous injection
BRII-835Drug
BRII-835 will be given via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with HBsAg loss at end of treatmentTime frame: Up to Week 48
- Proportion of participants with HBsAg loss at 24 weeks post-end of treatmentTime frame: Up to Week 72
- Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to Week 72
- Proportion of participants with serious adverse events (SAEs)Time frame: Up to Week 72
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
Investigative Site 61001
Kingswood, New South Wales, Australia
Investigative Site 61002
Birtinya, Queensland, Australia
Investigative Site 61003
Melbourne, Victoria, Australia
Investigative Site 86001
Beijing, Beijing Municipality, China
Investigative Site 86007
Beijing, Beijing Municipality, China
Investigative Site 86004
Chongqing, Chongqing Municipality, China
Investigative Site 86006
Guangzhou, Guangdong, China
Investigative Site 85201
Hong Kong, HONG KONG, China
Investigative Site 85202
Hong Kong, HONG KONG, China
Investigative Site 86008
Changchun, Jilin, China
Investigative Site 86013
Shanghai, Shanghai Municipality, China
Investigative Site 88601
Kaohsiung, Taiwan, China
Investigative Site 88602
Taipei, Taiwan, China
Investigative Site 88603
Taipei, Taiwan, China
Investigative Site 86011
Hangzhou, Zhengjiang, China
Investigative Site 65001
Singapore, Singapore, Singapore
Investigative Site 65002
Singapore, Singapore, Singapore
Investigative Site 82005
Seoul, South Korea
Investigative Site 82006
Soeul, South Korea
Investigative Site 82001
Busan, Busan, South Korea
Investigative Site 82002
Chuncheon, CHUNCHEON-SI, South Korea
Investigative Site 82004
Daegu, Daegu, South Korea
Investigative Site 82003
Seoul, Seoul, South Korea
nvestigative Site 66007
Chiang Mai, Thailand
Investigative Site 66008
Songkhla, Thailand
Investigative Site 66003
Bangkok, Bangkok, Thailand
Investigative Site 66005
Khon Kaen, Changwat Khon Kaen, Thailand
Investigative Site 66006
Nonthaburi, Changwat Nonthaburi, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.